Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Commentary|Videos|January 20, 2026

Why Startup Timelines Are Worsening—and How to Reverse the Trend

Analyze the operational pressures driving longer activation timelines, from protocol complexity to site competition, and learn how earlier, more flexible site engagement can restore momentum.

In a recent video interview with Applied Clinical Trials, Brian Mallon, Executive Vice President, Site and Patient Solutions at ICON, discussed why site activation timelines continue to lag across the industry and what operational changes could help reverse the trend. Drawing on findings from a recent global survey, Mallon outlined how prolonged contract and budget negotiations, communication gaps, and increasing protocol complexity are contributing to startup delays. He explained how greater standardization, earlier and more meaningful site engagement, and the thoughtful application of AI and automation—particularly to reduce administrative burden—can accelerate activation without adding complexity for sites. Mallon also emphasized the importance of maintaining momentum during startup, adopting more site-centric practices, and strengthening bi-directional communication to better support site staff while improving overall study efficiency.

The below interview transcript was lightly edited for clarity.

ACT: The survey notes worsening startup timelines compared to two years ago. What factors are driving this trend, and how can the industry reverse it?

Mallon: There does appear to be a trend toward elongated site activation timelines. It’s likely driven by increased protocol complexity, narrowing eligibility criteria, intensified competition for qualified sites, and heavier operational burdens placed on sites.

To reverse this, the industry needs to embrace more flexibility and engage sites earlier and more meaningfully, particularly at the feasibility and site identification stage. Historically, we asked blunt questions—do you have X, do you have Y—but at ICON we’ve moved toward being more probative: what do you need, and what would help with your participation?

Anticipating challenges and adapting to site-level information as it emerges allows sponsors and CROs to better support site needs and preserve momentum. Momentum really matters in study startup. If it’s lost, apathy can creep in.

At ICON, we’re not seeing worsening year-over-year timelines; we’re seeing improvement. What’s interesting is the variability across customers, which highlights how operating model decisions and pathways directly impact momentum. Visibility, trajectory, and communication of that momentum are critical for site engagement.


Related to this article

The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.